Recent studies have also shown that dose-adjusted ponatinib schedules (e.g. starting at 45 mg daily in T315I mutated CML, 30 mg in others, and reducing the dose to 15 mg daily once BCR::ABL1 transcripts [IS] are <1%) are as effective and significantly safer than a fixed dose of 45 mg daily (reduced only if toxicities) [65, 67, 80]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.